Figure 6.

Transforming growth factor (TGF)-β₁ expression and secretion. The expression and secretion of TGF-β₁ were measured in all groups of mice. A: Immunofluorescence shows co-localization of cytokeratin (CK)-19 (to mark bile ducts) and TGF-β₁ in large cholangiocytes in multidrug-resistance transporter 2/ABC transporter B family member 2 knockout (Mdr2^−/−) mice treated with mismatch compared with wild-type (WT) mismatch mice, whereas Mdr2^−/− mice treated with histamine-2 receptor (H2HR) vivo-morpholino have little co-localization. B: Serum secretion of TGF-β₁ does not change between WT groups; however, Mdr2^−/− mice treated with mismatch have increased levels of TGF-β1, which were decreased in mice treated with H2HR vivo-morpholino. ∗P < 0.05 versus WT mismatch; ^†P < 0.05 versus Mdr2^−/− + H2HR mismatch. Original magnification: ×40 (main images); ×80 (higher magnifications).